Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors

•Cure rates are high for choriocarcinoma, however chemoresistant disease often leads to death.•High expression of PD-L1 suggests a role for checkpoint inhibitors in choriocarcinoma.•Pembrolizumab should be considered for salvage therapy for chemoresistant choriocarcinoma.